126 related articles for article (PubMed ID: 36088851)
1. Druggable gene alterations in Japanese patients with rare malignancy.
Ohmoto A; Hayashi N; Fukada I; Yamazaki M; Yunokawa M; Kasuga A; Shinozaki E; Ueki A; Tonooka A; Takeuchi K; Mori S; Kiyotani K; Takahashi S
Neoplasia; 2022 Nov; 33():100834. PubMed ID: 36088851
[TBL] [Abstract][Full Text] [Related]
2. Driver and targetable alterations in Chinese patients with small bowel carcinoma.
Li J; Li X; Dong N; Yan S; Jing C; Ma T; Li W; Zhang C; Cai Y; Deng W
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6139-6150. PubMed ID: 36680582
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
Jan YH; Tan KT; Chen SJ; Yip TTC; Lu CT; Lam AK
Br J Cancer; 2022 Oct; 127(7):1304-1311. PubMed ID: 35842545
[TBL] [Abstract][Full Text] [Related]
4. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
[TBL] [Abstract][Full Text] [Related]
5. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
6. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
7. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
[TBL] [Abstract][Full Text] [Related]
8. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
[TBL] [Abstract][Full Text] [Related]
9. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
[TBL] [Abstract][Full Text] [Related]
10. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
11. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
[TBL] [Abstract][Full Text] [Related]
12. Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific.
Susanti S; Fadhil W; Murtaza S; Hassall JC; Ebili HO; Oniscu A; Ilyas M
J Clin Pathol; 2019 Mar; 72(3):263-264. PubMed ID: 30361395
[No Abstract] [Full Text] [Related]
13. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
Lieu CH; Golemis EA; Serebriiskii IG; Newberg J; Hemmerich A; Connelly C; Messersmith WA; Eng C; Eckhardt SG; Frampton G; Cooke M; Meyer JE
Clin Cancer Res; 2019 Oct; 25(19):5852-5858. PubMed ID: 31243121
[TBL] [Abstract][Full Text] [Related]
15. [Molecular analysis of sporadic colon cancer].
Hurtado C; Wielandt AM; Zárate AJ; Kronberg U; Castro M; Yamagiwa K; Ito T; Eishi Y; Contreras L; López-Köstner F
Rev Med Chil; 2015 Mar; 143(3):310-9. PubMed ID: 26005817
[TBL] [Abstract][Full Text] [Related]
16. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
17. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling and comprehensive genome-wide analysis of somatic copy number alterations in gastric intramucosal neoplasias based on microsatellite status.
Sugai T; Eizuka M; Arakawa N; Osakabe M; Habano W; Fujita Y; Yamamoto E; Yamano H; Endoh M; Matsumoto T; Suzuki H
Gastric Cancer; 2018 Sep; 21(5):765-775. PubMed ID: 29468422
[TBL] [Abstract][Full Text] [Related]
19. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
[TBL] [Abstract][Full Text] [Related]
20. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
